Elevidys was Sarepta Therapeutics’s largest region in fiscal 2025, bringing in $1.80B of $2.13B (84%).
| Geography | FY 2022 | FY 2025 |
|---|---|---|
| Elevidys | — | $1.80B |
| Pmo Products | $1.69B | $330.37M |
| Total | $1.69B | $2.13B |
Sarepta Therapeutics brought in $2.13B from its two regions in fiscal 2025, the year ended December 31, 2025. Sarepta Therapeutics regrouped these regions after fiscal 2022, so the total does not compare directly with that year's $1.69B. Elevidys was the largest at $1.80B (84.5%), ahead of Pmo Products at $330.37M (15.5%).
Sarepta Therapeutics began breaking out Elevidys in fiscal 2025, when it brought in $1.80B.
Us was Sarepta Therapeutics’s largest region in fiscal 2025, bringing in $1.80B of $2.13B (84%).
| Geography | FY 2022 | FY 2025 |
|---|---|---|
| Us | $1.49B | $1.80B |
| Outside Of U.S | — | $330.37M |
| Rest Of World | $193.34M | — |
| Total | $1.69B | $2.13B |
Sarepta Therapeutics brought in $2.13B from its two regions in fiscal 2025, the year ended December 31, 2025. Sarepta Therapeutics regrouped these regions after fiscal 2022, so the total does not compare directly with that year's $1.69B. Us was the largest at $1.80B (84.5%), ahead of Outside Of U.S at $330.37M (15.5%).
Sarepta Therapeutics began breaking out Outside Of U.S in fiscal 2025, when it brought in $330.37M. Sarepta Therapeutics stopped reporting Rest Of World as a separate region after fiscal 2022, when it brought in $193.34M.
July 2010 Agreement (Ebola & Marburg) was Sarepta Therapeutics’s largest revenue line in fiscal 2010, bringing in $19.64M of $58.84M (33%).
| Type Of Contract | FY 2010 |
|---|---|
| July 2010 Agreement (Ebola & Marburg) | $19.64M |
| June 2010 Agreement (H1N1) | $17.62M |
| May 2009 Agreement (H1N1) | $10.34M |
| November 2006 Agreement (Ebola, Marburg & Junin Viruses) | $6.41M |
| Grants | $3.24M |
| Other Agreements | $1.58M |
| Total | $58.84M |
Sarepta Therapeutics brought in $58.84M from its six revenue lines in fiscal 2010, the year ended December 31, 2010. July 2010 Agreement (Ebola & Marburg) was the largest at $19.64M (33.4%), ahead of June 2010 Agreement (H1N1) at $17.62M (29.9%) and May 2009 Agreement (H1N1) at $10.34M (17.6%). The other three revenue lines brought in $11.24M combined.
Sarepta Therapeutics (SRPT) reports its revenue by geography and by type of contract. In fiscal 2025, Elevidys was its largest region, bringing in $1.80B (84.5% of the total), followed by Pmo Products at $330.37M (15.5%).
Elevidys was Sarepta Therapeutics' largest region in fiscal 2025, bringing in $1.80B, or 84.5% of the $2.13B total across its two regions.
July 2010 Agreement (Ebola & Marburg) was Sarepta Therapeutics' largest revenue line in fiscal 2010, bringing in $19.64M, or 33.4% of the $58.84M total across its six revenue lines.
Every figure comes from Sarepta Therapeutics' annual financial filings, as reported. Each line keeps the name Sarepta Therapeutics gives it, and years follow its fiscal calendar.
Sarepta Therapeutics' revenue by geography goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.